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Hyperthermia induces deleterious effects at the cellular, organ, and 
whole-body level,1 and has a variety of causes, which include sepsis, 
classical and exertional heat illness, and drug-induced hyperthermia. 
While there is a survival benefit to a mild pyrexia in sepsis,2,3 mor-
tality increases as the core temperature (TCORE) exceeds 40°C,
2 sug-
gesting that at higher temperatures, the deleterious effects on organ 
and cellular function outweigh any benefit conferred from pyrexia. 
In noninfective hyperthermia, however, a TCORE of 38.5°C or greater, 
is associated with a worse outcome.3
Heatstroke represents the most severe form of heat illness with 
significant morbidity and mortality, including long-term multiorgan 
dysfunction and susceptibility to further heat illness. Exertional 
heatstroke (EHS) occurs in individuals undergoing strenuous phys-
ical activity, especially in hot and humid conditions, and is defined 
 
Received:	17	March	2020  |  Revised:	19	June	2020  |  Accepted:	22	June	2020
DOI: 10.1002/prp2.626  
R E V I E W
The efficacy of steroids in reducing morbidity and mortality 
from extreme hyperthermia and heatstroke—A systematic 
review
Edward Walter1  |   Oliver R. Gibson2
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided the original work is properly cited.
©	2020	The	Authors.	Pharmacology Research & Perspectives	published	by	John	Wiley	&	Sons	Ltd,	British	Pharmacological	Society	and	American	Society	for	
Pharmacology	and	Experimental	Therapeutics.
Abbreviations:	AKI,	acute	kidney	injury;	CBF,	cerebral	blood	flow;	CHS,	classical	heatstroke;	EHS,	exertional	heatstroke;	GI,	gastrointestinal;	IL-1,	interleukin-1;	IL-10,	interleukin-10;	
IL-1β, interleukin-1β;	IL-6,	interleukin-6;	INFγ,	interferon	gamma;	LPS,	lipopolysaccharide;	MAP,	mean	arterial	pressure;	NMS,	neuroleptic	malignant	syndrome;	TCORE, core temperature; 
TNF-α, tumor necrosis factor-alpha.
1Intensive Care Unit, Royal Surrey County 
Hospital,	Guildford,	UK













Severe hyperthermia from classical or exertional heatstroke, or from drug ingestion 




outcome.	 A	 systematic	 review	 searching	 Embase,	 MEDLINE,	 and	 PubMed	 from	
the	earliest	 date	 available	until	 September	2019	was	 conducted,	 according	 to	 the	
PRISMA	guidelines,	with	five	papers	identified.	In	four	studies,	systemic	steroids	ad-
ministered before or at the onset of heat stress improved mortality or reduced organ 
dysfunction. Survival time was greatest when steroid administration preceded heat 
stress.	In	one	study,	a	nonsignificant	increase	in	mortality	was	seen.	A	dose	response	
was	observed,	with	higher	doses	extending	survival	time.	Animal	studies	suggest	that	
steroids improve mortality and/or organ dysfunction after an episode of heat stress 
or extreme hyperthermia.
K E Y W O R D S
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as a TCORE above 40.5°C with neurological dysfunction. It is the third 
commonest cause of death in athletes.4 Classical heatstroke (CHS) 
presents with similar symptoms to EHS but in the absence of exer-
cise or exertion. CHS is often seen in meteorological heat waves and 
has a 28-day mortality rate of 58%, increasing to 71% at 2 years.5 
The clinical, biochemical, and physiological similarities between 
other noninfective hyperthermic states, for example, after drug in-
gestion, suggest that the pathological changes are at least partly due 
to	hyperthermia	per	 se,	 irrespective	of	 the	cause.	A	 large	number	
of drugs appear to have hyperthermic properties6,7; common cate-
gories include serotonergic (eg, antidepressant agents and opioids), 
anticholinergic (eg, antihistamine and antipsychotic agents), volatile 
anesthetic	agents,	and	neuroleptic	medications.	A	number	of	mech-
anisms are thought to be responsible for the hyperthermia, includ-
ing reduction in heat dissipation, and changes in uncoupling protein 
function8; the latter appears to allow diversion of protons normally 
involved	in	the	production	of	ATP	to	instead	be	dissipated	as	heat.9
Current treatment options for heatstroke and severe hyperther-
mia remain limited. The priority remains rapid cooling, to a TCORE 
below 38.6°C, ideally at a rate greater than 0.16°C·min−1,10,11 and 
supportive treatment. While a specific treatment may be efficacious 
in a particular condition, (eg, dantrolene in malignant hyperther-
mia, and cyproheptadine in serotonin syndrome), drug treatment 
is not generally recommended or of benefit in most cases.6,11 
Hyperthermia is associated with the development of organ dysfunc-
tion (see below), which may require supportive treatment.
Hyperthermia is directly cytotoxic, affecting membrane stability 
and transmembrane transport protein function with electrolyte ho-
meostasis,	protein,	and	DNA	synthesis	disrupted.	The	nuclear	matrix	
shows damage at lower temperatures than other parts of the cell, 
with significant endothermic changes observed at 40°C.12 Direct 
cell death in humans occurs at temperatures of around 41°C, with 
the rate of cell death increasing markedly with further temperature 
increases, primarily due to protein denaturation.13,14 The microvas-
culature is affected rapidly during hyperthermia, with capillary di-
lation, vascular stasis, and extravasation into the interstitium at a 
temperature of 40.5°C.15 Renal glomerular filtration rate reduces 
after a TCORE increase of 2°C and worsens further with increasing 
temperature.16	Acute	kidney	injury	(AKI)	affects	one	in	six	hospital-
ized	patients	with	EHS17 and has been reported in 53% after CHS.18 
Renal failure sufficient to require renal replacement therapy has 
also been described after hyperthermia due to neuroleptic malig-
nant syndrome,19 malignant hyperthermia,20 and recreational drug 
use.21 Hepatocellular dysfunction is common at temperatures above 
40°C,22 and coagulopathy occurs with a reported incidence of 45% 
in CHS.18 The integrity of the blood-brain barrier is disrupted,23 al-
lowing translocation of systemic toxins into the cerebral circulation.
The	gastrointestinal	(GI)	barrier	is	composed	of	physical	factors	
such as enterocyte membranes and tight junctions between entero-
cytes,	 along	 with	 an	 immunological	 defense	 system,	 to	 minimize	
translocation of toxic substances from the intestinal lumen to the 
internal environment. Systemic hyperthermia increases the permea-
bility of the gastrointestinal tract increasing the rate of gut bacterial 
translocation. Exposure leading to a TCORE exceeding 41.6°C-42.0°C, 
even after 60 minutes, induces a rapid sloughing of intestinal epi-
thelial surface and an increase in intestinal permeability, including to 
large molecules up to a molecular weight of 4000 Da.24 More mod-
est	increases	in	temperature	to	39°C-41°C	have	been	shown	in	vitro	
to cause an increase in paracellular permeability.25 The changes to 
permeability happen early, within a few hours, but are reversible—
paracellular permeability returns to normal even if the hyperthermia 
is maintained for 24 hours25 In addition to these direct effects of 
hyperthermia, blood flow to the intestinal tract is reduced at tem-
peratures above 40°C.26	This	exacerbates	the	loss	of	the	GI	barrier	
integrity and increases the potential for endotoxemia and systemic 
lipopolysaccharide	 (LPS)	 increases,	 which	 initiates	 the	 release	 of	
pro-inflammatory cytokines.27,28
Lipopolysaccharides	 are	 large	 molecules	 forming	 part	 of	 the	
outer	membrane	of	gram-negative	bacteria.	LPS	contains	a	hydro-
phobic domain, known as endotoxin,29 which stimulates release of 
pro-inflammatory mediators if they enter the systemic circulation. 
A	pro-inflammatory	 response	 is	 a	well-developed	defense	mecha-
nism, triggered by infective pathogens and toxic insults, such as 
trauma,	and	removes	injurious	stimuli	and	initiates	tissue	repair.	Pro-
inflammatory cytokines, for example, tumor necrosis factor-alpha 
(TNF-α)	and	interleukin-1	(IL-1),	are	released	primarily	from	macro-
phages and mast cells; cytokines and cell migration to the site of 
injury	promote	neutralization	of	 the	 antigen	 and	 tissue	 repair	 and	
healing.	In	one	study,	LPS	was	elevated	in	100%	patients	admitted	
to hospital after heatstroke, coinciding with a TCORE of 42.1°C.
30 
Significantly	increased	LPS	levels	have	also	been	found	in	the	portal	
circulation of heat-stressed rats at a TCORE of 41.5°C.
26 Heat stress 
in	primates	increases	portal	and	systemic	LPS	concentration.31	LPS	
is thought to be responsible for some of the deleterious effects of 
hyperthermia—administration	of	purified	LPS	produces	diffuse	en-
dothelial injury, tissue hypoperfusion, and refractory shock,28 and 
attenuation	of	systemic	LPS	by	anti-LPS	antibodies32 improves sur-
vival	after	heat	stress.	Administration	of	antibiotics	against	intestinal	
microorganisms prevents endotoxemia from occurring33 and appears 
to improve mortality,34,35 suggesting that endotoxemia occurring 
with heat stress is gut derived. Endurance exercise also produces 
endotoxemia,36,37 but whether this is primarily related to TCORE in-
creases is not certain. In one cross-over study, an increase in the in-
tensity of exercise increased the TCORE and intestinal permeability,
38 
and the cytokine profile of EHS and CHS is similar to that produced 
in endotoxemia,39 suggesting that irrespective of the initial stress, 
the	resulting	gut-derived	endotoxemia	may	be	similar.	Abolition	of	
endotoxemia significantly reduces cytokine production.39
The role of cytokines in heat stress is unclear with an incon-
sistent	response	to	thermal	stress.	A	number	of	pro-inflammatory	
and anti-inflammatory cytokines are elevated at the time of hyper-
thermia	from	heatstroke.	Acute	phase	reactants	may	also	increase.	
Of	 these,	 some	 (eg,	 interferon	 gamma	 [INFγ], interleukin-1β	 [IL-
1β]) are raised in a proportion of patients, whereas interleukin-6 
(IL-6)	may	be	elevated	in	all	patients.40 There is some correlation 
with	outcome;	 the	 rise	 in	 IL-6	and	 the	duration	of	 the	 increased	
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expression is related to mortality, independent of the maximum 
core temperature obtained.41	 Mice	 pretreated	 with	 IL-6	 before	
exposure to heat take longer to reach a TCORE of 42.4°C, showing 
less organ damage, and attenuation in the increase of other cyto-
kines.42	Antagonism	of	IL-1	also	improves	survival.43 Development 
of other hyperthermic states may also be associated with inflam-
matory	 mediators.	 Neuroleptic	 malignant	 syndrome	 (NMS)	 may	
be at least partly driven by an acute phase response; acute phase 
response mediators are reported to rise, and peak at 72 hours. 
Conversely, levels of anti-inflammatory agents such as serum iron 
and albumin initially decline then return to the normal range, co-
inciding with clinical improvement.44	 IL-6	and	TNF-α levels have 
also	been	found	to	be	significantly	increased	in	NMS,45	and	IL-6	in	
malignant hyperthermia.46
Glucocorticoids	 inhibit	many	of	 the	 initial	 events	 in	 an	 inflam-
matory response, promoting the resolution of inflammation.47 
Acutely,	glucocorticoids	 inhibit	the	vasodilation	and	increased	vas-
cular permeability that occurs following an inflammatory insult and 
decrease leukocyte migration to the site of injury.48 Most of the 
anti-inflammatory and immunosuppressive actions of glucocorti-
coids are attributable to alterations in the genetic transcription in 
leukocytes.48 While the precise role of the inflammatory response 
in heatstroke is unclear, reducing the inflammation appears to be of 
benefit. Corticosteroids reduce levels of the majority of cytokines,47 
and the administration of prophylactic glucocorticoids prevents 
heatstroke-induced	 LPS	 rise	 in	 an	 animal	 model.49,50 These data 
therefore suggest that administration of corticosteroids may have a 
beneficial role in the treatment of heatstroke.
2  | METHODS
Evidence for the clinical effectiveness of steroids in the acute treat-
ment of hyperthermia and heatstroke was assessed by conducting 
a systematic review of published research evidence. The review ad-
hered	to	the	PRISMA	checklist	(Appendix	A).51
2.1 | Identification of studies




ies were made by examining the reference lists of all retrieved arti-
cles and review articles identified by the original searches. “Cancer” 
terms were excluded from searches, to exclude the studies on hy-
perthermia as a treatment modality.
The	 search	 terms	 used	 for	 the	 three	 searches	 are	 summarized	
as	 follows,	 and	 detailed	 in	 Appendix	 B.	 The	 Embase	 database	was	
searched	from	1974	to	September	2019,	using	the	“explosion”	search	
terms of “heat stress,” “heat injury,” “hyperthermia,” and “steroid.” The 
MEDLINE	database	was	searched	from	1950	to	August	2019,	using	
the “explosion” search terms of “heat stress disorders” and “steroids.” 
The	PubMed	database	was	searched	from	1966	to	August	2019,	using	
the search terms “steroid*,” “heat illness,” “heat stroke,” and “heat 
stress”	in	the	titles	or	abstracts.	No	limits	on	any	searches	were	set.
2.2 | Inclusion and exclusion criteria
Two	reviewers	independently	screened	all	titles	and	abstracts.	Full-
text papers of any titles and abstracts that were considered relevant 
by either reviewer were obtained where possible. The relevance of 
each study was assessed according to the inclusion criteria stated in 
Table	1.	Studies	that	did	not	meet	the	criteria	were	excluded.	Any	
discrepancies were resolved by consensus.
2.3 | Types of intervention
Published	randomized	controlled	trials	 (RCTs)	where	steroids	were	
administered to animals or humans before or after the onset of heat 
stress, compared against placebo, were sought.
2.4 | Outcome measures
Trials where the steroids were assessed against survival data or 
evidence of organ dysfunction were included. These outcomes rep-
resent the most clinically relevant responses. Survival data were 




by using the Syrcle risk of bias tool.52
2.6 | Measures of treatment effect
We included any measure of mortality, including survival time, tem-
perature at which death occurred, and absolute survival numbers 





exposure to hyperthermia or heat stress
Comparators The intervention will be compared with 
the control group
Outcomes Survival or organ dysfunction
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after	cessation	of	heat	insult	or	trial.	A	P value of less than .05 was 
taken as statistically significant.
2.7 | Exclusion criteria
Studies were excluded in part or in total if the steroids were given 
in combination with another treatment. Results were only included 
if the effect of steroids alone was compared with the control group, 
either in a subgroup or the study as a whole.
2.8 | Subgroup analysis
Additional	statistical	analysis	between	the	intervention	and	control	
groups was undertaken where appropriate if not reported in the 
study. Statistical analysis performed by the review authors is high-
lighted in the text; all other analyses were extracted from the study. 
The Student's t test was used for continuous outcome data; the chi-
squared statistic for discrete outcome data.
3  | RESULTS
Electronic searches identified 8553 citations. Hand searches re-
vealed no further studies. Titles and abstracts were assessed for 
relevance to the review (stage 1 screening), and duplications were 
identified, resulting in 63 potential citations being retained. The full 
texts	of	these	citations	were	obtained.	After	applying	inclusion	cri-
teria to these full-text papers (stage 2 selection), 58 citations, which 
did	 not	 meet	 the	 inclusion	 criteria,	 were	 excluded.	 Five	 citations	
were	therefore	included	in	the	systematic	review	(Appendix	C).	No	
studies were found that investigated the secondary outcome that 
did not also investigate mortality.
Five	studies	were	found	which	met	the	criteria	(Tables	2	and	3).	
Of the five studies, three used rats53–55 and two used primates.50,56 
No	human	studies	were	found.	Four	of	the	studies	used	dexameth-
asone53–56 and one methylprednisolone.50 In three studies, the ste-
roid was given after the onset of heat stress.53–55 With the exception 
of one study,56 all studies reported improved survival (three reaching 
statistical significance) and markers of organ dysfunction.




pers described or compared characteristics of the intervention and 
control groups separately or were randomly housed, but there was 
not any indication that there were differences between the groups. 
None	of	the	papers	stated	that	the	investigators	were	blinded	to	the	
allocation, for example that the caregivers were separate to the in-
vestigators, but the reviewers considered that given that objective 
data were being collected in all cases, the reported outcomes are 
unlikely to have been affected by any lack of blinding. In four of the 
five papers, all study animals were accounted for, but in all papers, 
the results of all the proposed outcomes were reported.
The studies were considered too heterogeneous in their meth-
odology and outcome measures to enable completion of a metanaly-
sis.	A	descriptive	summary	was	therefore	completed.
3.1 | Mortality
Administration	of	4	mg	kg−1 of dexamethasone to rats, either before 
or after the onset of heatstroke (defined as the time a decrease in 
peak	mean	arterial	pressure	(MAP)	and	cerebral	blood	flow	(CBF)	in	
the striatum occurred), improved survival time from 101 ± 3 minutes 
(control) to 250 ±	9	minutes	and	122	± 3 minutes, respectively.53 
Administration	of	a	higher	dose	(6	mg	kg-1) before or after heatstroke 
onset further improved survival time to greater than 450 minutes, 
and 321 ± 5 minutes, respectively. These data highlight that the ad-
ministration of steroids prior to the onset of heatstroke lengthens 
survival time compared with administration after the onset, and that 
the higher dose (6 mg kg−1) had greater benefit than the lower dose 
(4 mg kg−1)	 (statistical	analysis	for	this	review).	Bilateral	adrenalec-
tomy	was	performed	in	a	further	subgroup;	MAP,	CBF,	and	time	to	
death were significantly lower in this group, but these changes were 
attenuated by dexamethasone.
A	later	study54 observed incremental doses of dexamethasone at 
the onset of heatstroke increased survival time to 104 ±	9	minutes	
(4 mg kg−1), 204 ± 25 minutes (6 mg kg−1), and 268 ± 27 minutes 
(8 mg kg−1) compared with untreated controls (24 ± 3 minutes) (sta-
tistical analysis for this review).
TA B L E  2   Study characteristics
Study Date of study Country Commercial/financial support
Lui 2000 Taiwan National	Science	Council	of	the	Republic	of	China
Veterans’	General	Hospital-National	Yang-Ming	University	joint	research	program
Tsou's	Foundation
Ministry of Education of the Republic of China
Lui 2014 Taiwan National	Science	Council	of	the	Republic	of	China
Bouchama 2007 Saudi	Arabia King	Faisal	Specialist	Hospital	&	Research	Center,	Riyadh,	Saudi	Arabia.
Yang 2010 Taiwan National	Science	Council	of	the	Republic	of	China
Gathiram 1998 South	Africa Chamber	of	Mines,	Johannesberg,	SA
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The third study to use rats55 administered 4 mg kg-1 dexametha-
sone at the onset of heatstroke, defined in the same way as the stud-
ies	by	Lui.53,54 Survival time showed a trend toward improvement 
from 22 ± 3 to 34 ± 6 minutes (P =	.09).	This	study	also	administered	
mannitol, an osmotically active diuretic and anti-inflammatory agent 
used after neurotrauma, to a further group which improved histo-
logical and biomarker assessment of neuronal damage, blood pres-
sure, and survival time further. This subgroup was excluded from our 
TA B L E  3   Study results (* statistically different to control; ns = not significant (P > .05))
Study Intervention
Number of subjects 
in intervention/
control group Species
Measure of mortality 
outcome Summary of findings
Lui	(2000) 4-6 mg kg−1 dexamethasone 
(preinsult)
10/10 Rat Time to death 101 ± 3 min (control)
250 ±	9	min	(4	mg	kg−1)*
> 450 min (6 mg kg−1)*
4-6 mg kg−1 dexamethasone 
(onset of insult)
10/10 Time to death 100 ± 4 min (control)
122 ± 3 min (4 mg kg−1)*
321 ± 5 min (6 mg kg−1)*
Lui	(2014) 4,6 or 8 mg kg−1 
dexamethasone (onset of 
insult)
8 in each group Rat Survival time 24 ± 3 min (control)
104 ±	9	min	(4	mg	kg−1)*
204 ± 25 min (6 mg kg−1)*
268 ± 27 min (8 mg kg−1)*
Bouchama	(2007) 2 mg kg-−1 dexamethasone 
(immediately preinsult, and 
continuing during cooling)
5/5 Baboon Time to death 10.9	± 7.3 h (control)
11 ± 5.4 h (2 mg kg−1)(ns)
5/5 Survival 3 (control)
2 (2 mg kg−1)(ns)
Yang	(2010) 4 mg kg−1 dexamethasone 
(onset of insult)
8/8 Rats Survival time 22 ± 3 min (control)
34 ± 6 min (4 mg kg−1)(ns)
Gathiram	(1988) 30 mg kg−1 
methylprednisolone (30m 
preinsult)
4/8 Monkeys Temperature at death 44.9	± 0.14°C (control)
44.4 ± 0.1°C 
(30 mg kg−1)*
TA B L E  4   Risk of bias assessment
Bouchama (2007) Gathiram (1988) Lui (2000) Lui (2014) Yang (2010)
1) Was the allocation sequence adequately 
generated and applied?
U U U U U
2) Were the groups similar at baseline or were they 
adjusted for confounders in the analysis?
U U U U U
3) Was the allocation to the different groups 
adequately concealed during?
U U U U U
4) Were the animals randomly housed during the 
experiment?
Y Y Y Y Y
5) Were the caregivers and/or investigators blinded 
from knowledge which intervention each animal 
received during the experiment?
U U U U U
6) Were animals selected at random for outcome 
assessment?
Y Y Y Y Y
7) Was the outcome assessor blinded? Y Y Y Y Y
8) Were incomplete outcome data adequately 
addressed?
Y Y Y U Y
9)	Are	reports	of	the	study	free	of	selective	
outcome reporting?
Y Y Y Y Y
10) Was the study apparently free of other 
problems that could result in high risk of bias?
Y Y Y Y Y
Note: Key:	Y:	Yes	(low	risk	of	bias),	N:	No	(high	risk	of	bias),	U:	Unclear	(unclear	risk	of	bias)
6 of 12  |     WALTER And GIBSOn
analysis since it did not meet the inclusion criteria for the review. 
All	 three	 studies	 induced	 heat	 stress	 by	 heating	 the	 anesthetized	
animals in a heat chamber at 42°C or 43°C. Heatstroke occurred 
between	70	and	90	minutes	later.	The	rise	in	temperature	in	the	in-
tervention group was not different to the control group.
In	the	first	of	two	studies	to	use	primates,	Gathiram50 adminis-
tered 30 mg kg−1	methylprednisolone	to	four	anesthetized	primates	
30 minutes before the onset of heating, by use of a heat cham-
ber at 41°C. The steroid-treated animals succumbed at a signifi-
cantly	 higher	 temperature	 (44.9	± 0.1 vs 44.4 ± 0.1°C) compared 
to controls. The rate of rise in TCORE and the time taken to reach 
heatstroke	was	not	 recorded.	 In	 the	study	by	Bouchama,56 10 ba-
boons were assigned randomly to dexamethasone or control group. 
Dexamethasone (2 mg kg−1) was administered in four divided doses 
every 6 hours starting immediately before heat stress and continu-
ing during cooling. The rate of heating, maximum temperature, and 
time above 40.4°C was not significantly different between the two 
groups. However, two animals (40%) in the control group survived, 
compared with only one in the steroid-treated group (P > .05). This 
study therefore opposes the positive findings observed in rat mod-
els. The use of a lower total dose, alongside the divided adminis-
tration over a prolonged postinsult period may have led to the null 
findings which contrast with positive outcomes in studies where a 





arterial	blood	pressure	 (MAP).	Three	studies53–55 demonstrated that 
heat	 stress	 reduced	MAP	 compared	 with	 nonheated	 controls;	 four	
studies50,53,54,56 showed that this hypotension was improved at spe-
cific time points with steroid administration. One study50 showed an 
improvement	 in	MAP	 at	 specific	 core	 temperatures,	which	 became	
statistically significant above 42°C. The heart rate was recorded in one 
study,50 which was lower at all temperatures compared with untreated 
but heated controls. Of the three papers recording cerebral blood flow 
(CBF),	 two53,54 document an improvement after the onset of heat-
stroke compared to untreated but heated controls.
3.2.2 | Neurological damage
Two studies investigated neuronal damage by histological changes 
against a previously defined score,53,55 with significant worsen-
ing compared with unheated controls and an improvement in the 
steroid-treated group in both groups, one reaching statistical signifi-
cance.53 Cerebral levels of three biochemical markers of neuronal 
damage (glutamate, glycerol, and lactate/pyruvate ratio) were shown 
to increase with heat stress, and were reduced significantly in the 
steroid-treated group54; this reduction in the heat stress-induced 
increase in cerebral biomarkers was not, however, seen in the study 
by	Yang.55 The difference in effect across studies may be explained 
by	the	dose	difference:	the	study	by	Yang	used	a	dose	of	4	mg	kg−1, 
compared with the higher dose (8 mg kg−1)	in	the	study	by	Lui,	where	
a difference was seen.
3.2.3 | Inflammatory cytokines
Administration	 of	 steroids	 in	 one	 study	 prevented	 a	 detectable	 in-
crease	in	serum	LPS,50 and in another caused an improvement in the 
heatstroke-activated inflammatory response as demonstrated by an 
improvement in the reduction in complement C3 and C4 levels and the 
increase	in	IL-6	during	cooling.56	IL-6	is	a	predominantly	anti-inflamma-
tory cytokine and appears to be protective in heat stress.42 Conversely, 
administration of steroid reduced serum levels of the pro-inflamma-
tory	mediators	IL-1ß,53,54	IL-10,54	and	TNF-α54; the exception was the 
low-dose	study	by	Yang,55	where	the	reduction	in	TNF-α was only ob-
served with the combination of mannitol and dexamethasone, but not 
with either agent alone. However, results in the latter nonsignificant 
F I G U R E  1   Risk of bias assessment, 
Key:	Black—low	risk	of	bias,	Grey—unclear	




Selecve outcome reporng (reporng bias)
Reporng of drop-outs (a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Blinded outcome assessment (detecon bias)
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Blinded group allocaon (selecon bias)
Number of studies  
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study are recorded after 4 mg kg−1, compared with the higher dose of 
8 mg kg−1 in the study where a difference was seen.
3.2.4 | Hepatic, renal, and coagulation system
Two studies detailed the effect of steroid administration on bio-
markers of renal and hepatic function, and on clotting factors. The 
first54 showed a statistically significant improvement in biomarkers 
in all three organ systems after steroid treatment compared with the 
heated control group; the second study conversely showed a dete-
rioration in markers of liver and renal function and coagulopathy, 
some reaching statistical significance.56
4  | DISCUSSION
Administration	of	corticosteroids	improved	survival	time	and	organ	
dysfunction due to heat stress, and a reduction in endotoxin and 
pro-inflammatory mediators in 80% of the studies included in the 
review. In addition, administration of another anti-inflammatory 
agent in combination with a corticosteroid in one study improved 
outcomes more than with one agent alone.55 The deterioration in 
the condition of the rats following adrenalectomy with improvement 
after the addition of dexamethasone53 further suggest that moder-
ating the inflammatory response in heat stress is of benefit. The re-
sults of the final study suggest a worsening in mortality and markers 
of organ failure, at variance with the other studies. There are meth-
odological and reporting differences between the studies, which 
make combining the conclusions less robust. There are differences 
in the outcome measure for mortality. Some studies used the time 
at which death occurred, others the time after onset of heat stress. 
The definition of heatstroke also differed across the studies: in one 
study, heatstroke was defined as the time that systolic blood pres-
sure	fell	below	90	mmHg,56	and	 in	others,	 the	time	at	which	MAP	
and	CBF	 fell.53–55 However, heatstroke in humans may be present 
without changes in blood pressure.
No	human	studies	were	 identified	 for	 the	 review,	and	the	applica-
tion of the studies to clinical practice in humans is uncertain. The two 
animal models used in the studies, rats and primates, have been shown 
to show similar inflammatory, metabolic, and cardiovascular features to 
humans when subjected to heat stress.57,58 However, the possibility of 
interspecies variation in the stress response and pharmacodynamics of 
corticosteroids cannot be eliminated; in addition, the current working 
definition of exertional heatstroke requires a core temperature of 40.5°C 
and central neurological dysfunction,10 which would not be possible to 
discern	 in	 an	 anesthetized	 animal	model.	 Furthermore,	 anesthesia	 has	
more recently been observed to affect the inflammatory response.59,60	All	
the	subjects	were	anesthetized	in	these	studies,	but	the	implications	are	
unclear. In three of the studies,53–55	the	subjects	were	anesthetized	using	
urethane, which is known to cause immunosuppression.61 The other two 
studies50,56 used ketamine, which is associated with reduction in the 
pro-inflammatory	TNF-α	and	IL-1,62 higher levels of which are associated 
with	adverse	outcomes,	but	also	a	reduction	of	IL-662; which in turn is 
associated with improved outcome upon systemic increase.
Further	 evidence	 that	 steroids	 may	 be	 effective	 in	 human	 heat	
stress come from a number of recently published case reports. In 
one, persistent cardiovascular failure and high serum cytokine levels, 
associated with a worse outcome,39,41–43 improved after the admin-
istration of hydrocortisone, and the patient was subsequently dis-
charged home.63 Similarly, out of five patients admitted with classical 
heatstroke, three were treated with blood purification therapy, who 
subsequently survived, while the two who only received conventional 
therapy died.64 The study authors propose that the improved outcome 
was due to the removal of pro-inflammatory cytokines,64 suggesting 
that glucocorticoids may have a similar effect.47,48
The administration of steroids before onset of heat stress in 
three of the studies made these data less relevant to clinical practice. 
Two of the remaining studies, where steroids were given after onset 
of the heat stress, showed an improvement in mortality and organ 
dysfunction, although the effect of steroids administered after the 
insult was lower.53
The optimal dose of corticosteroid from these studies is also 
uncertain. Two studies53,54 showed a dose-dependent improve-
ment.	 In	 the	 study	 by	 Yang55 where the effect of dexametha-
sone on cytokine levels and neuronal damage was not significant, 
the dose used was 50% of the dose used in the study with sim-
ilar methodology where significant differences were observed. 
The optimum glucocorticoid and duration of treatment were not 
addressed in any of the studies, and remain to be determined. 
Four	studies	used	dexamethasone,	and	one	used	methylprednis-
olone.	 Both	 steroids	 have	 predominantly	 glucocorticoid	 activity.	
Dexamethasone is long acting, with a biological half life between 
36 and 72 hours,65 with suppression of the hypothalamic-pituitary 
axis persisting for up to 2.5 days. However, the duration of the in-
flammatory response after an episode of heat stress is not known; 
raised levels of cytokines are still present after 36 hours,58 and 
whether a longer duration of treatment is required has not so far 
been addressed.
In one study of the effect of dexamethasone on primates showed 
a nonsignificant worsening in survival and a statistically significant 
worsening in markers of renal, hepatic, and coagulation function, 
at variance with all other identified studies. The reason for this dis-
crepancy is unclear. The expected fall in serum levels of cortisol did 
not occur in the study group compared with the control group, even 
after 12 hours, which the study authors suggest may be due to ste-
roid resistance or to dysregulation of the hypothalamic-pituitary-ad-
renal axis occurring as a result of the heat stress. The dose used in 
the study was the lowest of all the included studies and, in particular, 
lower than that used in the one other primate study, where a re-
duction in endotoxemia and mortality was observed.50 The success-
ful treatment study administered 30 mg kg−1 methylprednisolone, 
equivalent to 5.6 mg kg−1 dexamethasone, whereas 2 mg kg−1 was 
used in the study describing the worsening response following ste-
roids.	The	animals	were	anesthetized	with	ketamine,	 the	 influence	
of which on the immune function as discussed above is uncertain.
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Treatment of severe hyperthermia irrespective of the cause 
currently remains limited to rapid cooling and supportive mea-
sures in the majority of cases. Development of new treatments to 
reduce the associated morbidity and mortality is urgently required. 
Administration	 of	 corticosteroids	 appears	 promising	 and	warrants	
further investigation.
Gastrointestinal	 permeability	 and	 a	 pro-inflammatory	 response	
appear to occur as a consequence of increased thermal load, irrespec-
tive of the cause14,24–27,39; whether corticosteroids are efficacious in 
hyperthermia of any etiology is unclear but would also warrant further 
investigation. Identifying a particular cause of a raised temperature is 
often difficult, but may be noninfectious in up to two-thirds of cases,66 
suggesting that steroid administration might prove to be beneficial 
even when the cause cannot be identified.
5  | CONCLUSION
Heat stress is associated with a profound pro-inflammatory re-
sponse. Steroids appear to improve morbidity and mortality in most 
animal studies, but their relevance to humans in clinical practice is 
uncertain.	Further	studies	examining	dose	responses	to	corticoster-
oid administration in humans are warranted, notably where delivery 
occurs after the onset of heat stress.
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Identification 1a Identify the report as a protocol of a systematic review





Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list 
changes; otherwise, state plan for documenting important protocol amendments
Support:
Sources 5a Indicate sources of financial or other support for the review
Sponsor 5b Provide	name	for	the	review	funder	and/or	sponsor
Role of sponsor or 
funder
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
Introduction




Eligibility criteria 8 Specify	the	study	characteristics	(such	as	PICO,	study	design,	setting,	time	frame)	and	report	characteristics	(such	
as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers 
or other gray literature sources) with planned dates of coverage
Search strategy 10 Present	draft	of	search	strategy	to	be	used	for	at	least	one	electronic	database,	including	planned	limits,	such	that	
it could be repeated
Study records:
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review
Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase 
of the review (ie, screening, eligibility and inclusion in meta-analysis)
Data collection 
process
11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in 
duplicate), any processes for obtaining and confirming data from investigators
Data items 12 List	and	define	all	variables	for	which	data	will	be	sought	(such	as	PICO	items,	funding	sources),	any	preplanned	





Risk of bias in individual 
studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at 
the outcome or study level, or both; state how this information will be used in data synthesis
Data synthesis 15a Describe	criteria	under	which	study	data	will	be	quantitatively	synthesized
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling 
data and methods of combining data from studies, including any planned exploration of consistency (such as I2, 
Kendall's	τ)
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)
15d If quantitative synthesis is not appropriate, describe the type of summary planned
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within 
studies)
Confidence in cumulative 
evidence
17 Describe	how	the	strength	of	the	body	of	evidence	will	be	assessed	(such	as	GRADE)




Search Database Search term Number of results
6 EMBASE exp	"HEAT	STRESS"/ 9843
7 EMBASE exp	"HEAT	INJURY"/ 7262
8 EMBASE exp	HYPERTHERMIA/ 26 550
9 EMBASE (6 OR 7 OR 8) 41 854
26 EMBASE (cancer).ti,ab 2	205	759
34 EMBASE exp STEROID/ 1 416 567
35 EMBASE (9	AND	34) 2058
36 EMBASE 35	NOT	26 1967
42 EMBASE 35	NOT	26	[Clinical	trials	Clinical	Trial	OR	Randomized	Controlled	Trial	OR	
Controlled Clinical Trial OR Multicenter Study]
137
18 PubMed (heat illness).ti,ab 556
20 PubMed (heat stroke).ti,ab 3292
21 PubMed (heat stress).ti,ab 54 325
22 PubMed (hyperthermia).ti,ab 237 457
23 PubMed (18 OR 20 OR 21 OR 22) 290	007
28 PubMed (cancer OR tumour OR chemo*).ti,ab 4 353 854
39 PubMed (steroid*).ti,ab 332	196
40 PubMed (23	AND	39) 6407
41 PubMed 40	NOT	28 5340
43 PubMed (18	AND	39) 3
44 PubMed (20	AND	39) 24
45 PubMed (21	AND	39) 719
46 PubMed (22	AND	39) 5717
13 MEDLINE exp	"HEAT	STRESS	DISORDERS"/ 5306
37 MEDLINE exp STEROIDS/ 838 042
38 MEDLINE 13	AND	37 123
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APPENDIX C
PRISMA flowchart
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